Welcome to our dedicated page for Innate Pharma Sa news (Ticker: IPHA), a resource for investors and traders seeking the latest updates and insights on Innate Pharma Sa stock.
Innate Pharma S.A. (IPHA) news covers the company’s progress as a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. As a dual-listed issuer on Euronext Paris (IPH) and Nasdaq (IPHA), Innate Pharma regularly publishes regulatory and corporate updates that are relevant to investors following immuno-oncology and antibody-based therapeutics.
News about Innate Pharma frequently highlights developments across its antibody-engineering and ANKET® (Antibody-based NK cell Engager Therapeutics) platform. Company releases describe clinical and regulatory milestones for key assets such as IPH4502, a differentiated Nectin-4 ADC in solid tumors; lacutamab, a first-in-class anti-KIR3DL2 monoclonal antibody in cutaneous and peripheral T cell lymphomas; and monalizumab, an anti-NKG2A antibody developed in collaboration with AstraZeneca in non-small cell lung cancer.
Investors can expect updates on clinical trial progress, including Phase 1, Phase 2 and Phase 3 studies, regulatory designations for pipeline assets, and collaboration news involving partners such as Sanofi and AstraZeneca. Innate Pharma’s news flow also includes financial communications, such as business updates, financial results, financial calendars, and regulatory disclosures on the number of shares outstanding and voting rights under French market rules.
This news page aggregates these company communications in one place, making it easier to follow Innate Pharma’s clinical pipeline evolution, partnership activities and key corporate events. Readers interested in immuno-oncology, antibody-drug conjugates, NK cell engagers and collaboration-driven biotech models can use this feed to monitor how Innate Pharma reports its progress over time.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) will host a conference call on November 16, 2021, at 2 p.m. CET / 8 a.m. ET to update on business progress from Q3 2021. The call will feature CEO Mondher Mahjoubi and CMO Joyson Karakunnel. Investors can join via webcast or phone, with specific dial-in numbers provided. Innate Pharma focuses on oncology, leveraging therapeutic antibodies and Natural Killer cell biology, and has partnerships with major industry players like Bristol-Myers Squibb and AstraZeneca.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced its 2022 financial calendar, detailing key dates for financial statement publications. Significant dates include the release of 2021 financial statements on March 24, 2022, Q1 2022 revenue on May 10, 2022, and half-year financials on September 15, 2022. The Annual General Shareholders Meeting is scheduled for May 20, 2022. All reports will be issued before market open CET. Innate Pharma focuses on oncology, developing therapeutic antibodies that leverage the immune system for cancer treatment, with partnerships with notable industry leaders.
Innate Pharma (Euronext: IPH; Nasdaq: IPHA) announced the total number of shares and voting rights outstanding as of October 1, 2021. The company has 79,329,502 ordinary shares and a total of 80,087,342 theoretical voting rights. The release ensures compliance with French regulations set by the AMF. Innate Pharma is dedicated to oncology, focusing on immunotherapy through therapeutic antibodies, and maintains partnerships with notable biopharmaceutical firms. It is headquartered in Marseille, France, and has a US office in Rockville, MD.
On September 1, 2021, Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) reported its total number of outstanding shares and voting rights. The company has 79,294,402 ordinary shares and 6,784 Preferred Shares from 2016 and 7,581 from 2017. The total number of theoretical voting rights stands at 80,087,342, while exercisable voting rights amount to 80,068,767. This disclosure is in compliance with French regulations to ensure transparency in shareholding. Innate Pharma focuses on developing therapeutic antibodies for cancer treatment.
On September 17, 2021, Innate Pharma announced results from AstraZeneca's COAST Phase 2 trial presented at the ESMO Congress 2021. The interim analysis revealed that monalizumab combined with durvalumab significantly improved progression-free survival (PFS) and objective response rate (ORR) in patients with unresectable, Stage III non-small cell lung cancer (NSCLC) following chemoradiation therapy. AstraZeneca plans to initiate a registrational study based on these promising results, highlighting the potential of monalizumab as a groundbreaking treatment targeting NKG2A receptors on tumor-infiltrating immune cells.
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) announced promising results from the TELLOMAK trial, which showed a 35% overall global response rate for lacutamab in patients with mycosis fungoides. Financially, the company reported €15.7 million in revenue for H1 2021, a decline from €36.7 million in H1 2020, and a net loss of €23.7 million. Their cash position stands at €159.4 million.
Innate also launched new clinical trials for lacutamab and showcased advancements in their ANKET™ NK cell engager platform. Further data presentations are expected at upcoming conferences.
Innate Pharma SA (Euronext: IPH; Nasdaq: IPHA) announced a conference call on September 15, 2021, at 2 p.m. CEST to discuss business progress from H1 2021. Key executives participating include CEO Mondher Mahjoubi, CMO Joyson Karakunnel, and CFO Frédéric Lombard. The call will be accessible via a live webcast and telephone registration. Innate Pharma is focused on oncology and aims to improve cancer treatment through therapeutic antibodies. The company has alliances with major biopharmaceutical firms and a diverse pipeline of candidates.
Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) announced participation at the ESMO 2021 Virtual Congress to present new data regarding monalizumab in combination with durvalumab from the ongoing COAST Phase 2 trial. This research evaluates treatment for unresectable, Stage III non-small cell lung cancer (NSCLC). The results on progression-free survival will be highlighted on September 17, 2021. Additionally, pre-clinical data from Innate's ANKET platform will be showcased on September 18, 2021.
Innate Pharma announces participation in three virtual investor conferences in September 2021. The events include the Goldman Sachs 11th Annual Biotech Symposium on September 7, the Citi 16th Annual Biopharma Virtual Conference on September 8-9, and the H.C. Wainwright 23rd Annual Global Investment Conference on September 13. Innate Pharma is focused on oncology and has a strong pipeline of therapeutic antibodies aimed at improving cancer treatment outcomes, with major alliances in the biopharmaceutical sector.
Innate Pharma SA announced the total number of shares outstanding as of August 1, 2021. The company has 79,164,402 ordinary shares and 6,784 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total theoretical voting rights stand at 79,957,342 and exercisable voting rights at 79,938,767. This data complies with French regulations regarding share ownership and voting rights. Innate Pharma focuses on developing therapeutic antibodies aimed at treating cancer, leveraging its expertise in Natural Killer cell biology.